This was reported by the French newspaper La Tribune with reference to experts in the pharmaceutical market. According to the newspaper, the European pharmaceutical industry is about 80% dependent on the supply of active substances from China and India, and the disruption of transportation routes is already affecting the timing and cost of supplies.
Disruption of logistics and rising prices increase risks
As La Tribune notes, the problems stem not only from the rising cost of oil and gas following the escalating situation in the Middle East, but also from the slowdown in sea and air transportation through the region. Due to security threats, some logistics operators are changing delivery routes, which increases the delivery time of raw materials for the production of medicines.
Of particular concern is the dependence of European manufacturers on imports of chemical components and active pharmaceutical ingredients shipped through the Gulf countries. The publication notes that disruptions may affect the production of antibiotics, painkillers and drugs for chronic diseases.
“There are other delivery options, but their costs are higher and the supply chains for some substances are so complex that it could gradually lead to shortages,” said Denise Younal, a spokeswoman for France’s Center for Advanced Studies and International Information (CEPII).
Experts warn that in the event of further escalation of the conflict and continued restrictions in the Strait of Hormuz, pressure on the European pharmaceutical market will increase and the cost of drug production will continue to rise.
